CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells

Oral Oncology

Volumn 48, Issue 7, 2012, Pages 585-593

  Lin, Yu Chin ^a,b,c   Chen, Kuei Chiu ^a   Chen, Ching Chow ^b   Cheng, Ann Lii ^a   Chen, Kuen Feng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Akt; Bortezomib; CIP2A; HNSCC; PP2A

Indexed keywords

BORTEZOMIB; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOANTIGENS; BLOTTING, WESTERN; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; POLYMERASE CHAIN REACTION; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84862790962     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2012.01.012     Document Type: Article

References (40)

1. J. Bernier, C. Domenge, M. Ozsahin, K. Matuszewska, J.L. Lefebvre, and R.H. Greiner Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer N Engl J Med 350 19 2004 1945 1952 (Pubitemid 38580197)
2. J.S. Cooper, T.F. Pajak, A.A. Forastiere, J. Jacobs, B.H. Campbell, and S.B. Saxman Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck N Engl J Med 350 19 2004 1937 1944
3. R. Hitt, A. Lopez-Pousa, J. Martinez-Trufero, V. Escrig, J. Carles, and A. Rizo Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer J Clin Oncol 23 34 2005 8636 8645 (Pubitemid 46211506)
4. M.R. Posner, D.M. Hershock, C.R. Blajman, E. Mickiewicz, E. Winquist, and V. Gorbounova Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357 17 2007 1705 1715 (Pubitemid 350005152)
5. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 6 2006 567 578 (Pubitemid 43209104)
6. J.B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, and S. Rottey Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 11 2008 1116 1127
7. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, and D. Irwin A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2003 2609 2617 (Pubitemid 36741588)
8. A. Goy, A. Younes, P. McLaughlin, B. Pro, J.E. Romaguera, and F. Hagemeister Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 23 4 2005 667 675 (Pubitemid 46224166)
9. J.R. Berenson, H.M. Ma, and R. Vescio The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma Semin Oncol 28 6 2001 626 633 (Pubitemid 33138161)
10. T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, and T. Hayashi NF-kappa B as a therapeutic target in multiple myeloma J Biol Chem 277 19 2002 16639 16647 (Pubitemid 34967682)
11. R. LeBlanc, L.P. Catley, T. Hideshima, S. Lentzsch, C.S. Mitsiades, and N. Mitsiades Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model Cancer Res 62 17 2002 4996 5000 (Pubitemid 34984425)
12. J.B. Sunwoo, Z. Chen, G. Dong, N. Yeh, C. Crowl Bancroft, and E. Sausville Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma Clin Cancer Res 7 5 2001 1419 1428 (Pubitemid 32708698)
13. C. Allen, K. Saigal, L. Nottingham, P. Arun, Z. Chen, and C. Van Waes Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer Clin Cancer Res 14 13 2008 4175 4185
14. Z. Chen, J.L. Ricker, P.S. Malhotra, L. Nottingham, L. Bagain, and T.L. Lee Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms Mol Cancer Ther 7 7 2008 1949 1960
15. N.B. Davis, D.A. Taber, R.H. Ansari, C.W. Ryan, C. George, and E.E. Vokes Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study J Clin Oncol 22 1 2004 115 119 (Pubitemid 41095122)
16. C.N. Papandreou, D.D. Daliani, D. Nix, H. Yang, T. Madden, and X. Wang Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J Clin Oncol 22 11 2004 2108 2121 (Pubitemid 41095144)
17. M.H. Shah, D. Young, H.L. Kindler, I. Webb, B. Kleiber, and J. Wright Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors Clin Cancer Res 10 18 Pt 1 2004 6111 6118 (Pubitemid 39287516)
18. L. Soo Hoo, J.Y. Zhang, and E.K. Chan Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer Oncogene 21 32 2002 5006 5015
19. M.R. Junttila, P. Puustinen, M. Niemela, R. Ahola, H. Arnold, and T. Bottzauw CIP2A inhibits PP2A in human malignancies Cell 130 1 2007 51 62 (Pubitemid 47039258)
20. W. Li, Z. Ge, C. Liu, Z. Liu, M. Bjorkholm, and J. Jia CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells Clin Cancer Res 14 12 2008 3722 3728
21. C. Come, A. Laine, M. Chanrion, H. Edgren, E. Mattila, and X. Liu CIP2A is associated with human breast cancer aggressivity Clin Cancer Res 15 16 2009 5092 5100
22. Qu W, Li W, Wei L, Xing L, Wang X, Yu J. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol 2010 Dec 8. [Epub ahead of print].
23. Q.Z. Dong, Y. Wang, X.J. Dong, Z.X. Li, Z.P. Tang, and Q.Z. Cui CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis Ann Surg Oncol 18 3 2011 857 865
24. K.F. Chen, P.Y. Yeh, K.H. Yeh, Y.S. Lu, S.Y. Huang, and A.-L. Cheng Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells Cancer Res 68 16 2008 6698 6707
25. K.-F. Chen, C.Y. Liu, Y.-C. Lin, H.C. Yu, T.H. Liu, and D.R. Hou CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells Oncogene 29 47 2010 6257 6266
26. A. Khanna, C. Bockelman, A. Hemmes, M.R. Junttila, J.P. Wiksten, and M. Lundin MYC-dependent regulation and prognostic role of CIP2A in gastric cancer J Natl Cancer Inst 101 11 2009 793 805
27. Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, et al. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett 2011 Jan 18. [Epub ahead of print].
28. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011 Jan 11. [Epub ahead of print].
29. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011 Jan 14. [Epub ahead of print].
30. S. Ugi, T. Imamura, H. Maegawa, K. Egawa, T. Yoshizaki, and K. Shi Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes Mol Cell Biol 24 19 2004 8778 8789 (Pubitemid 39245095)
31. T. Gao, F. Furnari, and A.C. Newton PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth Mol Cell 18 1 2005 13 24 (Pubitemid 40444644)
32. P. Neviani, R. Santhanam, R. Trotta, M. Notari, B.W. Blaser, and S. Liu The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein Cancer Cell 8 5 2005 355 368 (Pubitemid 41579831)
33. A. Lievre, J.B. Bachet, D. Le Corre, V. Boige, B. Landi, and J.F. Emile KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 8 2006 3992 3995
34. E. Van Cutsem, C.H. Kohne, E. Hitre, J. Zaluski, C.R. Chang Chien, and A. Makhson Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
35. S. Huang, E.A. Armstrong, S. Benavente, P. Chinnaiyan, and P.M. Harari Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor Cancer Res 64 15 2004 5355 5362 (Pubitemid 39006556)
36. J. Wagenblast, M. Baghi, C. Arnoldner, S. Bisdas, W. Gstottner, and H. Ackermann Effect of bortezomib and cetuximab in EGF-stimulated HNSCC Anticancer Res 28 4B 2008 2239 2243
37. A.Z. Dudek, K. Lesniewski-Kmak, N.J. Shehadeh, O.N. Pandey, M. Franklin, and R.A. Kratzke Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor Br J Cancer 100 9 2009 1379 1384
38. J. Wagenblast, M. Baghi, C. Arnoldner, S. Bisdas, W. Gstottner, and H. Ackermann Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines J Cancer Res Clin Oncol 135 3 2009 387 393
39. C.W. Lindsley, S.F. Barnett, M.E. Layton, and M.T. Bilodeau The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors Curr Cancer Drug Targets 8 1 2008 7 18 (Pubitemid 351237905)
40. S.M. Brachmann, I. Hofmann, C. Schnell, C. Fritsch, S. Wee, and H. Lane Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells Proc Natl Acad Sci USA 106 52 2009 22299 22304